High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007 Abstract - Primary - Primary - Breast - INT-0163
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657 Esserman, L. J. , Berry, D. A. , Demichele, A. , Carey, L. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007 , CALGB-150012 , ACRIN-6657
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657) Esserman, L. J. , Perou, C. M. , Cheang, M. , Demichele, A. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) Freedman, Rachel A. , Seisler, D. K. , Foster, J. C. , Sloan, J. A. ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Primary - Primary - Older Adult - A151511 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741
Genome-wide profiling of archived material from CALGB 9840 and 9342 for paclitaxel (P) and trastuzumab (T) response biomarkers using gene expression and copy number analysis Harris, L. N. , Parker, J. R. , Broadwater, G. , Schulz, V. ... - - Cancer Res. - 2009 Abstract - Secondary-not-in-original - Comprehensive - PPP - CALGB-9342 , CALGB-9840 , CALGB-159806
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer Hughes, K. S. , Schnaper, L. , Cirrincione, C. T. , Berry, D. A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Breast - CALGB-9343
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer Martin, M. , Prat, A. , Rodriguez-Lescure, A. , Caballero, R. ... - - Breast Cancer Res. Treat. - 2013 Manuscript - Secondary-not-in-original - Comprehensive - Correl Sci NOS - CALGB-9342 , CALGB-9840
Lobular breast cancer and NAC: Combined results from the NKI and I-SPY 1 trial Mukhtar, R. A. , Lips, E. , Wesseling, J. , Livasy, C. , Yau, C. ... - - Cancer Res. - 2011 Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907 Muss, H. B. , Berry, D. A. , Cirrincione, C. T. , Theodoulou, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Older Adult - CALGB-49907
Intrinsic subtype and response to paclitaxel in CALGB 9344 tissue microarrays Nielsen, T. O. , Jewell, S. D. , Thor, A. D. , Gao, D. , Perou, C. M. ... - ASCO Breast - Breast Cancer Symposium - 2009 Abstract - Secondary - Primary - Correl Sci NOS - CALGB-159905 , C9344
Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840 Rimm, D. L. , Broadwater, G. , Friedman, P. N. , Berry, D. A. ... - SABCS - Cancer Res. - 2009 Abstract - Secondary - Primary - Breast - CALGB-9840
Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101 Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - - J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - Breast - CALGB-40101
Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy. Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - SABCS - - 2010 Abstract - Primary - Preliminary - Breast - CALGB-40101
Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer Sikov, W. , Perou, C. M. , Golshan, M. , Collyar, D. , Berry, D. A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Preliminary - Breast - CALGB-40603
